Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
Darren Brenner, MD
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
From Doctor-Speak to Patient-Speak: Bridging the Communication Gap
Luis A. Gonzalez, MD, MPH
Jeremiah Brown Jr., MD, MS, FASRS
Trial in Progress: Phase 3 MoonRISe-3 Study
First Results From Cohort 4 of the SunRISe-1 Trial
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
Vera Bril, MD
Neelam Goyal, MD
Ocular to Generalized MG: How and Why the Disease Evolves
Hans Katzberg, MD
Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology
Nicholas J. Silvestri, MD
Non-CF Bronchiectasis: How Radiologists Can Drive Better Outcomes
Robert D. Suh, MD
Lea Azour, MD
Ashwin Basavaraj, MD
Acromegaly Care: Individualized Diagnosis and Management Strategies
July 13, 2025
San Francisco, California
Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Jonathan Strober, MD
Managing Side Effects in FcRn Therapy: Best Practices for gMG
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS, FASCO
Evan Y. Yu, MD
Personalizing Care Within the RCC Treatment Paradigm
Eric Jonasch, MD
Brad McGregor, MD
Ulka Vaishampayan, MBBS
What’s New in Glaucoma Therapy?
Paul Petrakos, DO, MS
Justin Schweitzer, OD, FAAO
I. Paul Singh, MD
Sarah H. Van Tassel, MD
What’s New in Subconjunctival MIBS
What’s New In Glaucoma?
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results
Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management
Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role
Chairperson’s Perspective: Treating At-Risk MASH: What Are You Waiting For?
Mazen Noureddin, MD, MHSc
New Solutions for Optimizing IOP Control: A Case-Based Approach
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.